All News
Inflammatory Arthritis and Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) (also called acne inversa), is a chronic inflammatory skin disorder affecting apocrine gland-bearing skin in the axillae, groin, and under the breasts and is characterised by
Read Article
Biosimilar Bonanza in 2023 (12.9.2022)
Dr. Jack Cush reviews more than a dozen news and journal articles from this past week on RheumNow.com.
Read Article
Telemedicine Updates
Several recent articles inform us of recent trends in Telemedicine.
Read Article
Review of 120 pts w/ Catastrophic antiphospholipid syndrome showed that 54% had skin involvement & was 1st APS sx in 35%. Findings: livedo racemosa (45%), necrosis/ulcers (42%), splinter hemorrhages (29%), distal edema (23%), purpura (14%). https://t.co/HsVWlebfL2 https://t.co/dixoeHNkFQ
Links:
Dr. John Cush RheumNow ( View Tweet)
The Top 10 Research Priorities in Psoriatic Arthritis
A survey of 317 carers and clinicians focused on psoriatic arthritis has set an agenda of the top 10 research questions for psoriatic arthritis (PsA).
https://t.co/qvcB3OkJUS https://t.co/EuD3qhOb5a
Links:
Dr. John Cush RheumNow ( View Tweet)
Why treatment of pre-RA isn't ready for prime time
The ACR Great Debate was on "To treat or not to treat in pre-RA?" and it was stressed that autoimmunity may start well before clinical symptoms occur.
https://t.co/TcKRc0w4i9 https://t.co/OkmlxTiAbm
Links:
Dr. John Cush RheumNow ( View Tweet)
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler ( @lianegensler discusses the following abstracts presented at #ACR22. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
https://t.co/f7o8UARKNl https://t.co/ryVmD86UoI
Links:
Dr. John Cush RheumNow ( View Tweet)
Systematic review of MSK findings in patients with acute lymphoblastic leukemia finds 29 pts with peripheral arthritis (7), axial manifestations (17), and osteolytic lesions (21 pts) & Vertebral Fx (4) Hypercalcemia in 9 cases. https://t.co/GJXoqhOjNG https://t.co/YHS09E4a0U
Links:
Dr. John Cush RheumNow ( View Tweet)
Tight control of proteinuria in newly diagnosed lupus nephritis
The last 3 years have been exciting times in the field of lupus nephritis (LN) with two new licensed therapies, belimumab (BAFF-inhibitor) and voclosporin (calcineurin-inhibitor).
https://t.co/Q7TahfZiB0 https://t.co/9Odwed55fe
Links:
Dr. John Cush RheumNow ( View Tweet)
Steroids in RA: Friend or foe (or both)?
Abstract 2000 presents longer-term follow-up data from the recently published GLORIA trial.
https://t.co/kNxwYMf59m https://t.co/rzRsZymlz3
Links:
Dr. John Cush RheumNow ( View Tweet)
RA: MACE Events with Opioids vs. NSAIDs
The authors of abstract 1646 assessed MACE (myocardial infarction, stroke, heart failure, CVD death, VTE) and all-cause mortality in new users of opioids vs. matched NSAIDs new users.
https://t.co/huz6NyYRlh https://t.co/dNYu7ybFZ5
Links:
Dr. John Cush RheumNow ( View Tweet)
Diffuse alveolar hemorrhage in antiphospholipid syndrome
https://t.co/Fx2fGcaNGS https://t.co/jFHUhvs5xV
Links:
Dr. John Cush RheumNow ( View Tweet)
Eosinophilia in systemic JIA patients after exposure to biologics
Dr. Bella Mehta discusses Abstract 0872 at #ACR22.
https://t.co/FI7KfDURr3 https://t.co/FqnqMPHJ3h
Links:
Dr. John Cush RheumNow ( View Tweet)
Inadequate Dosing of Hydroxychloroquine Leads to Hospitalizations in SLE
https://t.co/qJ8YbJ2Y6A https://t.co/deZKc1835I
Links:
Dr. John Cush RheumNow ( View Tweet)
Joint hypermobility linked to depression & anxiety? Longitudinal Study of 6105 kids at age 14 yrs: 19% had generalised joint hypermobility (more in F) *+& assoc w/ depression (OR: 3.53), anxiety (3.14) at age 18 https://t.co/9NrEfwt4L5 https://t.co/JrM2JKUuJ0
Links:
Dr. John Cush RheumNow ( View Tweet)
SLE preg delivery hospitalizations (77560) was associated with increased risk of CV complications, including preeclampsia [aOR 2.12] , peripartum cardiomyopathy (4.42), CHF (4), arrhythmias (2.2), AKI (7.7), stroke (4.8), VTE (6.9) w/ incr hosp costs https://t.co/PF6P8oDWZB https://t.co/jA2pHcciB1
Links:
Dr. John Cush RheumNow ( View Tweet)
Xeljanz Cancer Risks Detailed
The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study.
https://t.co/OG2OkD5Tcw https://t.co/1dZcJ5jDUj
Links:
Dr. John Cush RheumNow ( View Tweet)
Bimekizumab Efficacy in TNF-Refractory PsA
Bimekizumab, a selective inhibitor of IL-17F and IL-17, has shown superior efficacy and safety in a 16 week trial in patients with active PsA who previously failed therapy with TNFi inhibitors.
https://t.co/NCJvhmisNe https://t.co/Tk2d7ILHl2
Links:
Dr. John Cush RheumNow ( View Tweet)
From 1055 new polyarthralgia presentations, 88 (8.3%) Dx w/ psoriatic arthritis. PsA Dx assoc w/ a +FamHx ( OR 4.14), psoriasis (OR=78.94), erosions (OR=5.74), US +power Doppler (OR=7.11). Neg assoc w/ +RF (OR 0.03), +CCP (OR 0.06). https://t.co/YXcqUq9JCi https://t.co/PLuU6cTDab
Links:
Dr. John Cush RheumNow ( View Tweet)
3388 pts in J Hopkins Scleroderma study found 29% w/ calcinosis (13.5% these w/ heavy burden calcinosis/HBC). Calcinosis assoc w/ diffuse SSc, disease severity (PH, ILD, CVD, GI, renal crisis, myopathy)(OR 2.9- 6.9) & PM/Scl Abs (OR 17.31) https://t.co/ksdPcH9W0O https://t.co/OvI9wytf5H
Links:
Dr. John Cush RheumNow ( View Tweet)